Physician profile
Constance Bright
NPI 1275927675
$1,242.10
in general payments reported to CMS, 2019-2025
14 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.87 · 2022: $378 · 2023: $188 · 2024: $447 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $310.83 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.51 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Genzyme Corporation | $139.31 | 2022-2025 | |
| Janssen Biotech, INC. | $132.16 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $113.94 | 2022-2024 | Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $101.31 | 2021-2023 | Linzess |
| Madrigal Pharmaceuticals | $79.89 | 2024-2025 | Resmetirom, Rezdiffra |
| Qol Medical, LLC | $74.28 | 2024 | Sucraid |
| Fresenius Kabi USA, LLC | $32.07 | 2024 | Idacio |
| Intercept Pharmaceuticals, INC. | $28.35 | 2022-2023 | Ocaliva |
| Lilly USA, LLC | $25.95 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $19.47 | 2024 | Dificid |
| Ardelyx, INC. | $17.95 | 2023 | Ibsrela |
| Amgen INC. | $17.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.